INSTRUCTIVE CASE

Pyoderma gangrenosum with splenic involvement

Shaikha Jameel AlDossary a,b,*, Tariq S. AlFawaz b, Awatif K. AlMutairi c

a Dammam University, Department of Pediatrics, King Fahd University Hospital, Khobar, Saudi Arabia
b King Fahad Medical City, Riyadh, Saudi Arabia
c Children Hospital King Fahad Medical City, Riyadh, Saudi Arabia

Received 27 November 2015; received in revised form 29 February 2016; accepted 24 March 2016
Available online 29 April 2016

KEYWORDS
Pyoderma gangrenosum (PG); Spleen involvement; Children

Abstract Pyoderma gangrenosum (PG) is a non-infectious disease characterized by necrotizing, ulcerative, and painful skin. The incidence of PG is approximately 3–10 cases per million people per year. Pyoderma gangrenosum is rarely observed in children, accounting for less than 4%, but it primarily affects adults between the ages of 25 and 54 years old without gender preference. Here, we present a case report of a 16-month-old toddler diagnosed with pyoderma gangrenous with splenic involvement. The young age of the patient and extracutaneous manifestation are of high interest.

1. Introduction

Pyoderma gangrenosum (PG) is a non-infectious disease characterized by necrotizing, ulcerative, and painful skin [1–3]. The incidence of PG is approximately 3–10 cases per million people per year [4]. Pyoderma gangrenosum is rarely observed in children, accounting for less than 4% of cases, but it primarily affects adults between the ages of 25 and 54 years old without gender preference. [1,2,5,6] However, the cause of pyoderma gangrenosum is poorly understood. Some researchers attributed the cause to dysfunction in the immune system [7,8]. In most cases, PG manifests as small lesions that become larger and spread. Pyoderma gangrenosum can be subcategorized as ulcerative, bullous, pustular, and vegetative [9,10]. A PG diagnosis is usually of exclusion, as there are no specific criteria to confirm diagnosis. Using systemic steroids is the most effective treatment of PG in children [1,2].
Clinical information was retrieved via a retrospective review of medical records to determine clinical manifestation.

2. Case

A 16-month-old girl with no previous medical history presented with a fever associated with recurrent feet and hand abscesses that rapidly ruptured and formed deep ulcers. Skin examination at the ulcerous stage revealed multiple large tender necrotic oval ulcers with a purulent base and sharply defined violaceous undermined edges in the hands and feet (Fig. 1). Initial work-up showed leukocytosis with predominant neutrophils, an ESR of 83 mm/h and a CRP of 29.7 mg/L. Abscesses did not respond to antimicrobial therapy. Abdominal US revealed splenic abscess measuring 10.47 × 10.82 cm (Fig. 2). The culture from both skin lesions and the splenic lesion were negative, and the histopathology demonstrated characteristics of PG. However, all immune tests were within normal ranges. The patient was started on oral prednisolone (2 mg/kg/day) for two weeks and showed a good response, in which the fever resolved and all of the lesions healed.

3. Discussion

Pyoderma gangrenosum is neutrophilic dermatosis that is destructive in nature with unknown causes. More than half of patients with PG develop the disorder in association with an underlying systemic disease [11]. However, the diagnosis is made after excluding other causes of ulcerative skin lesions via histopathological findings. There is no diagnostic laboratory test that is specific for PG. The presence of neutrophils and increased ESR was observed in most of the affected patients [12]. In our patient, we made a diagnosis of pyoderma gangrenosum based on skin histopathology. However, idiopathic pyoderma gangrenosum was suggested due to exclusion of other usual associations.

Extracutaneous manifestation of PG in our patient was in the form of splenic involvement. Allen CP et al reported a child to have pyoderma gangrenosum with splenic and lung involvement [13], and Johnson JL et al reported a child with only splenic involvement [14]. There is limited data regarding extracutaneous manifestation of PG in the pediatric age group compared to adult patients, who frequently report this comorbidity.

Patients with superficial pyoderma gangrenosum are primarily treated with topical immunosuppressants (e.g., corticosteroids, calcineurin inhibitor, et al) whereas systemic treatment requires systemic therapy such as corticosteroids and cyclosporine [15]. Alternative therapies include dapsone, sulfapyridine, methotrexate, clofazimine, minocycline, colchicine, intravenous immunoglobulins, and anti-TNF agents [1]. This was described well in small uncontrolled studies and clinical experiences. Our patient improved completely after administration of systemic corticosteroid treatment, as observed by the rapid healing of the ulcer, resolving of the fever, and disappearance of the splenic abscess.

The number of pediatric patients with extracutaneous manifestation of PG is limited. Further studies and reports will enrich our knowledge in the clinical presentation of this disease as well as guidelines for improved management.

Conflict of interest

None to be declared by the authors.

References

[1] Sandhu K, Handa S, Kanwar AJ. Idiopathic pyoderma gangrenosum in a child. Pediatr Dermatol 2004;21:276–7.
[2] Torrelo A, Colmenero I, Serrano C, Vilanova A, Naranjo R, Zambrano A. Pyoderma gangrenosum in an infant. Pediatr Dermatol 2006;23:338–41.
[3] Wanke NCF, Souza MAA, Regnier GC, Maceira J. Pioderma Gangrenoso: a respeito de dez casos. An Bras Dermatol 1994; 69:175–8.

[4] Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009;23:1008.

[5] Souza CS, Chiossi MPV, Takada MH, Foss NT, Roselino AMF. Pyoderma gangrenosum: case study and review of clinical, laboratorial and therapeutic aspects. An Bras Dermatol 1999; 74:465–72.

[6] Barbato MT, Bakos L, Masiero NCMS, Bolson P. Clinic and pathological profile of the patients with pyoderma gangrenosum at Hospital de Clinicas de Porto Alegre (RS) Brazil. An Bras Dermatol 2000-2006;2008(83):431–6.

[7] Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012;13:191.

[8] Adachi Y, Kindzeliski AL, Cookingham G, Shaya S, Moore EC, Todd 3rd RF, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 1998;111:259.

[9] Bhat RM, Nandakishore B, sequeira FF, Sukumar D, Kamath GH, Martis J, et al. Pyoderma gangrenosum: an Indian perspective. Clin Exp Dermatol 2011;36:242–7.

[10] Bakhshi S, Sethuraman G, Singh MK, Arya LS. Atypical pyoderma gangrenosum as a manifestation of childhood acute lymphoblastic leukemia. Pediatr Dermatol 2005;22:543–5.

[11] Carneiro FR, Santos MA, Sousa BA, Nascimento Cdo S, Amin GA, Moutinho AT. Pyoderma gangrenosum in a newborn- case report. An Bras Dermatol 2013 Nov- Dec; 88(6 Suppl 1):173–5. http://dx.doi.org/10.1590/abd1806-4841.20132601.

[12] Lambropoulos V, Patsatsi A, Tsona A, Papakonstantinou A, Filippopoulos A, Sotiriadis D. The adverse consequences of pyoderma gangrenosum in a 13 year old child. Int J Surg Case Rep 2011;2(7):221–4.

[13] Allen CP, Hull J, Wilkison N, Burge SM. Pediatric pyoderma gangrenosum with splenic and pulmonary involvement. Pediatr Dermatol 2013 Jul–Aug;30(4):497–9. http://dx.doi.org/10.1111/pde.12138. Epub 2013 Apr 29.

[14] Johnson JL, West DA, Haggstrom AN. Pyoderma gangrenosum associated with an aseptic splenic abscess in a patient with neurofibromatosis. Pediatr Dermatol 2015 Jan-Feb;32(1):113–7. http://dx.doi.org/10.1111/pde.12129. Epub 2013 Mar 28.

[15] Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006;333(July (7560)):181–4.